Issuu on Google+

Immunology Strengthens Fight Against Stage 4 Colon Cancer

Immunotherapy is without question a renowned new medical strategy that utilizes the human immune system to conquer disease. In summation, over a string of 30 years, extensive research conducted by both clusters of physicians and scientists has proven that this approach is clinically successful for numerous diseases. Advances in adoptive immunotherapy, which concentrates on the expansion and infusion of specific diseasefighting white blood cells in patients, have rocketed this scientific arena to its peak in terms of being an effective treatment for viral diseases, colon cancer, and astoundingly even stage 4 cancer types. We can expect, taking into consideration the undeniable results and continued advances, the importance of immunotherapy to grow exponentially - particularly as it applies to late stage colon and other stage 4 cancers. To date, stage 4 colon cancer is not much more than chemo and radiation and the statistics are so grim - renowned care providers do not dare report survival data beyond the first couple of years as it is more sobering than promising. New immunotherapy treatments, however, are bringing new hope as they deliver a key part of the treatment puzzle - along with better results and quality of life for patients.

Envita Leads the Field in Stage 4 Colon Cancer A string of published findings have illustrated the effects of adoptive immune therapy in cancer patients. Envita's devoted medical team assessed the most reliable of said studies and regarded the strengths and weaknesses of each. Their immaculate research prompted a protocol that incorporates only the most effective procedures for the expansion and application of cells as a potent immunotherapy. Our protocols are based on the most recent published literature in the arena, from a lot of the most prestigious hospitals and universities both nationwide and globally. Predictably, our


treatment has been specially formulated to deal specifically with colon cancer and stage 4 cancer patients' immune systems.

Envita's Two-fold Stage 4 Colon Cancer and Stage 4 Cancer Immunotherapy Envita Natural Medical Center established in Mexico is utilizing NK cells and CTLs in real time as immunotherapy treatment for colon cancer and stage 4 cancer patients. Envita's proprietary immune therapy vaccine is appropriately labeled AAIT (for autologous adoptive immune therapy,) and there are 4 major cell types involved – the significant majority being natural killer cells and T cells. The types of cells that make up Envita's treatment include Natural Killer cells, Natural killer T cells, Cytokine-induced killer cells, and Cytotoxic T lymphocytes. The vaccine(s) is created by expanding a patient’s own antitumor immune cells into mega amounts. These cells are then analyzed for activation markers and highlighted for their ability to destroy colon cancer and other stage 4 cancer cells under controlled lab conditions, then re-infused into the patient.

AAIT Immunology Available for Colon cancer and Stage 4 Cancer Patients at Envita Mexico Envita Natural Medical Center is currently using NK, NKT, and T lymphocytes as supportive immunotherapy for our cancer patients. Envita’s proprietary Stage 4 colon cancer vaccine is registered as AAIT - one that increases a patient’s own antitumor immune cells into the billions over a span of several weeks. These cells are evaluated for activation markers, analyzed for their ability to incapacitate stage 4 colon cancer cells in the laboratory, and then ultimately re-infused into the patient. Heralded by scientific research and clinical results, Enivta's AAIT immunotherapy presents a valuable option for cancer patients who are keenly devoted to conquering colon and other stage 4 cancers, while balancing an intact immune system. Envita administers only top tier combinations of conventional and alternative cancer treatment heightened by advanced natural cancer treatment to help patients secure better health and improve their overall quality of life.


Immunology Strengthens Fight Against Stage 4 Colon Cancer